

## Who we are



*We are a science-led global healthcare company with a special purpose: to help people do more, feel better and live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.*

## What we do



*We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible with our three global businesses, scientific and technical know-how and talented people.*

## How we do it



*Everyone at GSK is focused on 3 priorities – Innovation, Performance, Trust*

***Innovation:*** *We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.*

***Performance:*** *We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.*

***Trust:*** *We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer.*

***Our values and expectations*** *are at the heart of everything we do and help define our culture – so that together we can deliver extraordinary things for our patients and consumers and make GSK a brilliant place to work.*

# GSK in Canada Fast Facts

## Economy



GSK Canada employs approx. 2,000 full time employees across the country, providing a salary injection of \$225 million into the Canadian economy.

GSK Canada was ranked among Forbe's top 100 best employers in Canada for 2018.

## Research & Development



We have invested more than \$2 billion since 2001 in Canadian pharmaceutical and vaccines R&D, ranking GSK among the top 10 contributors to R&D in Canada across all industries.

In 2017 alone, GSK in Canada invested over \$65 million to R&D.

We helped establish 22 Research Chairs in Faculties of Medicine and Pharmacy at Canadian universities in respiratory healthcare, vaccinology, HIV, oncology, and management of chronic disease amongst others.

In 2018, invested over \$ 15 million into 54 active clinical trials across Canada involving 2,793 active subjects.

Supported 15 Investigator Sponsored Studies with physicians across Canada in 2018.

## Product Portfolio



Helping to transform the treatment of respiratory diseases, GSK has a full, broad and innovative respiratory portfolio spanning established and new compounds and delivery systems



GSK Canada also has a comprehensive vaccines portfolio, helping to protect children, teenagers, adults & elderly and travellers against certain diseases.



Spanning across six categories (pain relief, respiratory, digestive health, oral health, nutrition and skin health), GSK produces consumer healthcare brands including VOLTAREN, NEOCITRAN, TUMS, SENSODYNE and BUCKLEY's.

## Community Investment



An Imagine Canada Caring Company since 1990, GSK contributes over 1% of pre-tax profits annually to initiatives in health and local community organizations.

GSK has joined with Save the Children to help First Nations communities in Canada improve their emergency plans and be better prepared to meet the unique needs of children before, during and after disasters by providing child protection training and preparedness supplies, empowering Indigenous children with the knowledge and skills to stay safe in emergencies.

## Ways of Working



GSK is among a group of 10 Innovative Medicines Canada members along with ViiV Healthcare Canada who, since 2017, have voluntarily agreed to publicly report aggregate payments made to health care professionals and health care organizations. GSK is proud to transparently disclose this data to demonstrate our ongoing commitment to transparency in our operations – we believe it enhances trust in our healthcare system and confidence for patients.

We believe GSK's disclosure in Canada of aggregate payments was a great first step and are proud to be leaders in expanding our reporting of payments made to individual HCPs, despite the lack of disclosure requirements in Canada. We will begin individual level reporting in June 2020 for transfers of value made to HCPs throughout 2019.

## Oncology



GSK is at the forefront of some of the most exciting developments in Oncology; using the immune system to treat cancer promises to transform lives by providing less toxic and more targeted treatments than radiation or chemotherapy.

For many years' patients have been offered current solutions which can have debilitating side effects, help only some people and often only to a small degree.

So, one way we hope to design new medicines, is by harnessing a patient's own immune system to target and destroy tumours. And, by creating new combinations of medicines that work better together, we hope to transform cancer treatment for patients in the future.